In recent years, the T1799A B-type Raf kinase (BRAF) mutation in thyroid cancer has
received enthusiastic investigation, and significant progress has been made toward …

Papillary thyroid cancer (PTC) is the most common endocrine malignancy, accounting for 85–
90% of all thyroid cancers. Genetic alternations involving the mitogen-activated protein …

Genetic alteration is the driving force for thyroid tumorigenesis and progression, based upon
which novel approaches to the management of thyroid cancer can be developed. A recent …

Papillary thyroid cancer (PTC) is a common endocrine malignancy that frequently harbors
the oncogenic T1799A BRAF mutation. As a novel prognostic molecular marker, this …

Context: Use of BRAF mutation in papillary thyroid cancer (PTC) has the potential to improve
risk stratification of this cancer. Objective: The objective of the study was to investigate the …

Significant progress has recently been made in the clinical management of papillary thyroid
carcinoma. The accuracy of diagnosis and prognostic stratification of this type of carcinoma …

Background: The BRAF mutation has been shown to be associated with aggressive
clinicopathologic characteristics of papillary thyroid cancer (PTC). However, several studies …

Context: Because very few studies have examined the correlation between BRAF mutations
and clinicopathological features of papillary thyroid carcinoma (PTC), we analyzed here a …

A high prevalence of activating mutation of the B type Raf kinase (BRAF) gene was recently
reported in papillary thyroid cancer (PTC). However, the frequency of this mutation in several …

The V600E mutation of the B-type Raf kinase (BRAF) gene is a common event in papillary
thyroid carcinoma (PTC) and seems to play a key role in the development and progression …